Article
Oncology
Cornelia Eckert, Catriona Parker, Anthony Moorman, Julie A. E. Irving, Renate Kirschner-Schwabe, Stefanie Groeneveld-Krentz, Tamas Revesz, Peter Hoogerbrugge, Jeremy Hancock, Rosemary Sutton, Guenter Henze, Christiane Chen-Santel, Andishe Attarbaschi, Jean-Pierre Bourquin, Lucie Sramkova, Martin Zimmermann, Shekhar Krishnan, Arend von Stackelberg, Vaskar Saha
Summary: The study analyzed the outcomes of children with high-risk relapsed acute lymphoblastic leukaemia (ALL), and found that a good minimal residual disease (MRD) response was associated with better disease-free survival and overall survival. After hematopoietic stem cell transplantation (SCT), there were differences in the rates of relapse and death between B-cell precursor (BCP) and T-cell ALL.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Cell Biology
Yingchi Zhang, Shicheng Wang, Jingliao Zhang, Chao Liu, Xinqi Li, Wenbo Guo, Yongjuan Duan, Xiaoyan Chen, Suyu Zong, Jiarui Zheng, Yixuan Wu, Xiaoli Chen, Xuelian Cheng, Yanxia Chang, Yue Wang, Feng Ding, Wenyu Yang, Xiaojuan Chen, Ye Guo, Li Zhang, Yumei Chen, Yao Zou, Xiaofan Zhu, Jin Gu, Tao Cheng
Summary: In this study, Zhang et al. used single-cell transcriptomics and B-cell receptor sequencing to analyze the transcriptomic profiles of B-cell acute lymphoblastic leukaemia cells at diagnosis, residual, and relapse stages. They found that the hypoxia pathway could be a potential target for residual leukaemia cells.
NATURE CELL BIOLOGY
(2022)
Article
Hematology
Alexander Popov, Veronika Fominikh, Ekaterina Mikhailova, Larisa Shelikhova, Grigory Tsaur, Yulia Abugova, Elena Zerkalenkova, Yulia Olshanskaya, Dmitry Balashov, Galina Novichkova, Alexey Maschan, Natalia Miakova
Summary: Blinatumomab followed by haematopoietic stem cell transplantation was used in 13 infants with acute lymphoblastic leukaemia, showing a 75% event-free survival rate at 18 months for patients treated in first remission with complete MRD response before transplantation. This data supports further studies of immunotherapy in high-risk infant ALL.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Hematology
Huanping Wang, Yile Zhou, Xin Huang, Yi Zhang, Jiejing Qian, Jianhu Li, Chenying Li, Xueying Li, Yinjun Lou, Qiaoyun Zhu, Yujie Huang, Haitao Meng, Wenjuan Yu, Hongyan Tong, Jie Jin, Hong-Hu Zhu
Summary: In adult T-cell acute lymphoblastic leukemia (T-ALL) patients, inductions end-stage MRD based on FCM is an independent prognostic factor for relapse and survival. EOI-MRD positivity can predict post-transplant relapse in patients undergoing allo-HSCT for the first remission.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Review
Pediatrics
Pietro Merli, Marianne Ifversen, Tony H. Truong, Hanne V. Marquart, Jochen Buechner, Matthias Woelfl, Peter Bader
Summary: MRD assessment is crucial in risk stratification and treatment guidance for pediatric patients with acute lymphoblastic leukemia. Higher levels of MRD negatively impact post-transplant survival, but controversies exist regarding the interchangeability of different MRD detection methods and the optimal quantification level.
FRONTIERS IN PEDIATRICS
(2021)
Article
Multidisciplinary Sciences
Q. Heydt, C. Xintaropoulou, A. Clear, M. Austin, I Pislariu, F. Miraki-Moud, P. Cutillas, K. Korfi, M. Calaminici, W. Cawthorn, K. Suchacki, A. Nagano, J. G. Gribben, M. Smith, J. D. Cavenagh, H. Oakervee, A. Castleton, D. Taussig, B. Peck, A. Wilczynska, L. McNaughton, D. Bonnet, F. Mardakheh, B. Patel
Summary: Bone marrow adipocytes play a crucial role in acute lymphoblastic leukaemia (ALL) pathogenesis and therapy by limiting the ALL proteome to promote cell survival.
NATURE COMMUNICATIONS
(2021)
Article
Hematology
Martijn W. C. Verbeek, Chiara Buracchi, Anna Laqua, Stefan Nierkens, Lukasz Sedek, Juan Flores-Montero, Mattias Hofmans, Elaine Sobral de Costa, Michaela Novakova, Ester Mejstrikova, Susana Barrena, Saskia Kohlscheen, Monika Szczepanowski, Jan Kulis, Elen Oliveira, Romana Jugooa, Anja X. de Jong, Tomasz Szczepanski, Jan Philippe, Jacques J. M. Van Dongen, Alberto Orfao, Monika Brueggemann, Giuseppe Gaipa, Vincent H. J. Van der Velden
Summary: The standardized EuroFlow protocol with CD19 as the primary B-cell marker allows for sensitive and reliable MRD assessment in BCP-ALL patients undergoing chemotherapy. An alternative gating strategy has been developed for analyzing MRD in patients treated with CD19-targeting therapies, showing high concordance with original MRD data despite variations. This indicates that overall MRD analysis remains accurate even with differences in CD19 expression.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Oncology
Anthony Moorman, Ellie Butler, Emilio Barretta, Amy A. Kirkwood, Claire Schwab, Thomas Creasey, Daniel A. Leongamornlert, Elli Papaemmanuil, Pip Patrick, Laura Clifton-Hadley, Bela Patel, Tobias F. Menne, Andrew K. McMillan, Christine J. Harrison, Clare J. Rowntree, David Marks, Adele K. Fielding, Eleanor J. Ward, Katie Twentyman, Amir Enshaei
Summary: Chromosomal abnormalities have a significant prognostic impact on patients with B-cell precursor ALL, with specific abnormalities like KMT2A-AFF1, complex karyotype, and low hypodiploidy/near-triploidy associated with poor outcomes. Patients with BCR-ABL1 have similar outcomes to others, while JAK-STAT abnormalities are linked to a high relapse rate of 56%.
Article
Oncology
Vinod Vijay Subhash, Libby Huang, Alvin Kamili, Marie Wong, Dan Chen, Nicola C. Venn, Caroline Atkinson, Chelsea Mayoh, Pooja Venkat, Vanessa Tyrrell, Glenn M. Marshall, Mark J. Cowley, Paul G. Ekert, Murray D. Norris, Michelle Haber, Michelle J. Henderson, Rosemary Sutton, Jamie Fletcher, Toby N. Trahair
Summary: This study demonstrates the feasibility of designing tumor-specific PCR-based MRD tests using whole-genome sequencing data, which shows high sensitivity in detecting residual cancer cells and good concordance with traditional MRD detection methods in ALL patients.
BRITISH JOURNAL OF CANCER
(2022)
Article
Medicine, General & Internal
Yongzhan Zhang, Lu Bai, Yifei Cheng, Aidong Lu, Yu Wang, Jun Wu, Xiaohui Zhang, Yingxi Zuo, Lanping Xu, Yueping Jia, Xiaojun Huang, Leping Zhang
Summary: This study found that allo-HSCT, especially haplo-HSCT, can improve survival and reduce relapse in high-risk T-ALL children. Minimal residual disease re-emergence, age, and high white blood cell count are independent risk factors that affect prognosis.
CHINESE MEDICAL JOURNAL
(2022)
Article
Hematology
Roland P. Kuiper, Patricia G. Hoogeveen, Reno Bladergroen, Freerk van Dijk, Edwin Sonneveld, Frank N. van Leeuwen, Judith Boer, Irina Sergeeva, Harma Feitsma, Monique L. den Boer, Vincent H. J. van der Velden
Summary: The study revealed that fusion genes and genomic deletions can be used as alternative MRD targets in ALL patients who do not have sensitive IG/TR targets, leading to appropriate patient stratification and potentially impacting treatment decisions.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Review
Pediatrics
Katharina Kleinschmidt, Meng Lv, Asaf Yanir, Julia Palma, Peter Lang, Matthias Eyrich
Summary: Allogeneic hematopoietic stem cell transplantation (HSCT) is a potential curative option for high-risk or refractory/relapsed leukemias in children, with haploidentical HSCT (hHSCT) showing significant advantages but posing the key question of how to deplete donor T-cells effectively. In vivo T-cell suppression and ex vivo T-cell depletion are two established methods to reduce alloreactivity in hHSCT, with different protocols utilizing post-transplantation cyclophosphamide or anti-thymocyte globulin. Studies have not shown a clear benefit for any specific method in terms of overall survival, non-relapse mortality, or disease recurrence.
FRONTIERS IN PEDIATRICS
(2021)
Review
Pediatrics
Adriana Balduzzi, Jochen Buechner, Marianne Ifversen, Jean-Hugues Dalle, Anca M. Colita, Marc Bierings
Summary: This review explores the best treatment options and new developments in hematopoietic stem cell transplantation for children under the age of four with acute lymphoblastic leukemia.
FRONTIERS IN PEDIATRICS
(2022)
Article
Hematology
Lu Bai, Zhi-Xiao Zhang, Guan-Hua Hu, Yi-Fei Cheng, Pan Suo, Yu Wang, Chen-Hua Yan, Yu-Qian Sun, Yu-Hong Chen, Huan Chen, Kai-Yan Liu, Lan-Ping Xu, Xiao-Jun Huang
Summary: Data analysis of 200 children with high-risk acute myeloid leukaemia undergoing haploidentical haematopoietic stem cell transplantation showed a 4-year overall survival of 71.9%, event-free survival of 62.3% and cumulative incidence of relapse of 32.4%. Minimal residual disease positivity before transplantation was significantly associated with lower survival and higher risk of relapse. Haploidentical stem cell transplantation can be considered as a therapy option, and pre-transplantation minimal residual disease status significantly affects outcomes.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Renato Bassan, Sabina Chiaretti, Irene Della Starza, Orietta Spinelli, Alessandra Santoro, Francesca Paoloni, Monica Messina, Loredana Elia, Maria Stefania De Propris, Anna Maria Scattolin, Ernesta Audisio, Laura Marbello, Erika Borlenghi, Patrizia Zappasodi, Elisa Mauro, Giovanni Martinelli, Daniele Mattei, Nicola Fracchiolla, Monica Bocchia, Paolo De Fabritiis, Massimiliano Bonifacio, Anna Candoni, Vincenzo Cassibba, Paolo Di Bartolomeo, Giancarlo Latte, Silvia Trappolini, Anna Guarini, Antonella Vitale, Paola Fazi, Alfonso Piciocchi, Alessandro Rambaldi, Robin Foa
Summary: This study demonstrates that pediatric-inspired chemotherapy is the standard of care for younger adults with Philadelphia chromosome-negative acute lymphoblastic leukemia/lymphoma (Ph- ALL/ LL). The addition of pegaspargase improves survival rates, particularly in younger patients and those without residual disease.
Article
Pathology
Jack Grant, Anne Stanley, Kevin Balbi, Gareth Gerrard, Philip Bennett
Summary: The study evaluated the performance of the Biocartis Idylla system in detecting known EGFR mutations using extracted DNA at different input levels. Results showed that within the manufacturer's specified scope, the Idylla EGFR test generated concordant findings for 90.77% of NSCLC cases at 20 ng DNA input, 98.46% at 50 ng input, and 100% at 250 ng input.
JOURNAL OF CLINICAL PATHOLOGY
(2022)
Letter
Oncology
Linea Natalie Toksvang, Kathrine Grell, Stine Nygaard Nielsen, Jacob Nersting, Daniel Murdy, Anthony V. Moorman, Ajay Vora, Kjeld Schmiegelow
Letter
Oncology
Mary M. Taj, Anthony V. Moorman, Lina Hamadeh, Arnaud Petit, Vahid Asnafi, Fanny Alby-Laurent, Ajay Vora, Marc R. Mansour, Rosemary Gale, Sylvie Chevret, John Moppett, Andre Baruchel, Elizabeth Macintyre
Article
Oncology
Linea N. Toksvang, Kathrine Grell, Jacob Nersting, Matilda Degn, Stine N. Nielsen, Jonas Abrahamsson, Bendik Lund, Jukka Kanerva, Olafur G. Jonsson, Kristi Lepik, Goda Vaitkeviciene, Laimonas Griskevicius, Petter Quist-Paulsen, Ajay Vora, Anthony Moorman, Daniel Murdy, Martin Zimmermann, Anja Moricke, Bruce Bostrom, Jaitri Joshi, Lisa L. Hjalgrim, Kim P. Dalhoff, Bodil Als-Nielsen, Kjeld Schmiegelow
Summary: The study found that in ALL patients, as the weighted mean DNA-TG increased, the risk of relapse decreased in MRD-positive patients, but not in MRD-negative patients. This indicates that DNA-TG may serve as a biomarker for maintenance therapy intensity.
Article
Hematology
Thomas Creasey, Emilio Barretta, Sarra L. Ryan, Ellie Butler, Amy A. Kirkwood, Daniel Leongamornlert, Elli Papaemmanuil, Pip Patrick, Laura Clifton-Hadley, Bela Patel, Tobias Menne, Andrew K. McMillan, Christine J. Harrison, Clare J. Rowntree, Nick Morley, David Marks, Adele K. Fielding, Anthony Moorman
Summary: Despite being a childhood disease, acute lymphoblastic leukemia (ALL) also has a second peak in adults aged 60 years and over. However, existing treatment strategies have poor outcomes in this age group. Studies have shown that these older adults with ALL have common genetic abnormalities, indicating the need for novel therapeutic strategies to improve prognosis.
Article
Oncology
Anthony Moorman, Ellie Butler, Emilio Barretta, Amy A. Kirkwood, Claire Schwab, Thomas Creasey, Daniel A. Leongamornlert, Elli Papaemmanuil, Pip Patrick, Laura Clifton-Hadley, Bela Patel, Tobias F. Menne, Andrew K. McMillan, Christine J. Harrison, Clare J. Rowntree, David Marks, Adele K. Fielding, Eleanor J. Ward, Katie Twentyman, Amir Enshaei
Summary: Chromosomal abnormalities have a significant prognostic impact on patients with B-cell precursor ALL, with specific abnormalities like KMT2A-AFF1, complex karyotype, and low hypodiploidy/near-triploidy associated with poor outcomes. Patients with BCR-ABL1 have similar outcomes to others, while JAK-STAT abnormalities are linked to a high relapse rate of 56%.
Article
Oncology
Richard Gallon, Rachel Phelps, Leigh Betts, Christine Hayes, Dino Masic, Julie A. E. Irving, Ciaron McAnulty, Vaskar Saha, Ajay Vora, Katharina Wimmer, Jayashree Motwani, Christine Macartney, John Burn, Michael S. Jackson, Anthony Moorman, Mauro Santibanez-Koref
LEUKEMIA & LYMPHOMA
(2023)
Meeting Abstract
Hematology
Angus Hodder, Avijeet K. Mishra, Katherine Clesham, Susan Baird, Kaljit Bhuller, Ismail Bisho, Denise Bonney, Anna Castleton, Michelle Cummins, Emmy Dickens, Lindsay George, Sara Ghorashian, Brenda Gibson, Chris Hasley, Nicholas Heaney, Rachael E. Hough, Danielle Ingham, Galina Jigoulina, Katherine Lindsay, Donna Lancaster, Majid Madni, Andrea Malone, Bethany Mitchell, Anthony Moorman, John Moppett, Vanessa McLelland, Jayashree Motwani, Emma Nicholson, Caroline Osborne, Katharine Patrick, Lamia Samrin, Sanjay Tewari, Indu Rakesh Thakur, Sujith Samarasinghe, Ajay Vora, David O'Connor
Meeting Abstract
Hematology
Daniel Leongamornlert, Jesus Gutierrez-Abril, SooWah Lee, Emilio Barretta, Thomas Creasey, Krisztina Zuborne Alapi, Max F. Levine, Juan E. Arango-Ossa, Juan S. Medina-Martinez, Amy A. Kirkwood, Laura Clifton-Hadley, Pip Patrick, David Jones, Adam P. Butler, Christine J. Harrison, Peter J. Campbell, Bela Patel Wrench, Anthony Moorman, Adele K. Fielding, Elli Papaemmanuil
Meeting Abstract
Hematology
Anna Ostergaard, Amir Enshaei, Rob Pieters, Ajay Vora, Martin A. Horstmann, Gabriele Escherich, Bertil Johansson, Mats Heyman, Kjeld Schmiegelow, Peter M. Hoogerbrugge, Monique L. den Boer, Roland P. Kuiper, Anthony Moorman, Judith M. Boer, Frank N. van Leeuwen
Meeting Abstract
Hematology
David O'Connor, Jonas Demeulemeester, Lucia Conde, Amy A. Kirkwood, Kent Fung, Foteini Papaleonidopoulou, Gianna Bloye, Nadine Farah, Sunniyat Rahman, Jeremy Hancock, Caroline Bateman, Sarah Inglott, Jon Mee, Javier Herrero, Peter Van Loo, Anthony Moorman, Ajay Vora, Marc R. Mansour
Meeting Abstract
Hematology
Angus Hodder, Avijeet K. Mishra, Susan Baird, Ismail Bisho, Denise Bonney, Katherine Clesham, Michelle Cummins, Emmy Dickens, Brenda Gibson, Lindsay George, Danielle Ingham, Galina Jigoulina, Donna Lancaster, Katherine Lindsay, Majid Madni, Andrea Malone, Bethany Mitchell, John Moppett, Jayashree Motwani, Anthony Moorman, Katharine Patrick, Lamia Samrin, Sanjay Tewari, Indu Rakesh Thakur, David O'Connor, Ajay Vora, Sujith Samarasinghe
Article
Hematology
Anna ostergaard, Amir Enshaei, Rob Pieters, Ajay Vora, Martin A. Horstmann, Gabriele Escherich, Bertil Johansson, Mats Heyman, Kjeld Schmiegelow, Peter M. Hoogerbrugge, Monique L. den Boer, Roland P. Kuiper, Anthony V. Moorman, Judith M. Boer, Frank N. van Leeuwen
Summary: IKZF1 deletions have a significant negative impact on the survival of patients with ETV6::RUNX1 and high hyperdiploid ALL. The presence of IKZF1 deletions is associated with lower event-free survival rates, higher minimal residual disease values, and higher relapse rates in both ETV6::RUNX1 and high hyperdiploid ALL. Stratifying patients by minimal residual disease may not be sufficient for predicting outcomes in high hyperdiploid ALL, suggesting the need for additional risk stratification.
Article
Hematology
David Marks, Laura Clifton-Hadley, Mhairi Copland, Jiaull Hussain, Tobias F. Menne, Andrew McMillan, Anthony Moorman, Nicholas Morley, Dina Okasha, Bela Patel, Pip Patrick, Michael N. Potter, Clare J. Rowntree, Amy A. Kirkwood, Adele K. Fielding
Summary: This study evaluated the activity and safety of reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation (HSCT) in patients older than 40 years with acute lymphoblastic leukaemia. The results showed that this transplantation method provided good disease control with moderate graft-versus-host disease (GVHD) and achieved better-than-expected event-free survival and overall survival in this high-risk population.
LANCET HAEMATOLOGY
(2022)
Article
Hematology
David Marks, Amy A. Kirkwood, Clare J. Rowntree, Melanie Aguiar, Katharine E. Bailey, Brendan Beaton, Paul Cahalin, Anna Z. Castleton, Laura Clifton-Hadley, Mhairi Copland, Anthony H. Goldstone, Richard Kelly, Emma Lawrie, SooWah Lee, Andrew K. McMillan, Mary Frances McMullin, Tobias F. Menne, Rachel J. Mitchell, Anthony Moorman, Bela Patel, Pip Patrick, Paul Smith, David Taussig, Deborah Yallop, Krisztina Zuborne Alapi, Adele K. Fielding
Summary: The UKALL14 study aimed to determine the benefit of adding rituximab, an anti-CD20 monoclonal antibody, to the therapy of adults with acute lymphoblastic leukaemia. Results showed that adding rituximab did not significantly improve event-free survival for adults with de novo B-precursor acute lymphoblastic leukaemia.
LANCET HAEMATOLOGY
(2022)